BIOCORP and ROCHE DIABETES CARE FRANCE launch Mallya, an innovative medical device to improve the daily life of diabetic patients


[]).push(function () { viAPItag.display(“vi_1088641796”) }) || []).push(function () { viAPItag.display(“vi_1088641796”) })

ISSOIRE, France – (BUSINESS WIRE) – Regulatory news:

BIOCORP (Paris: ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specializing in the design, development and manufacture of innovative medical devices, and Roche Diabetes Care France, a benchmark company in the support of diabetic patients, announces the launch in France of Mallya, a medical device available in pharmacies. Developed by BIOCORP, this smart insulin pen collects and transfers insulin data with nearly 100% accuracy2. Rechargeable via its USB port, Mallya is compatible with most disposable insulin pens1. This innovation aims to simplify the daily life of diabetic patients on insulin therapy and could make it possible to avoid errors or omissions.

The health companies BIOCORP and Roche Diabetes Care France are finalizing their collaboration – announced last June – with the distribution of Mallya smart devices for insulin injection pens since the beginning of April. Manufactured in Clermont-Ferrand (France), this innovation for patients on insulin is the first in its category to receive the CE mark (medical device).

Reusable and compatible with 91%1 disposable insulin pens, Mallya automatically collects insulin data (dose, date, time) and transfers them to the Gluci-Chek application developed by Roche Diabetes Care France, ensuring qualified information on which the patient can rely and the doctor can then make decisions3. With the integration into the Roche Diabetes Care France digital ecosystem, patients benefit from solutions that alleviate the mental burden of their disease, in a context where more than 750,000 people4 are treated with insulin injections in France (excluding insulin pumps).

“The commercial launch of Mallya represents an important step for BIOCORP. We are very proud to lead it with Roche Diabetes Care France. Its leading position, its vast pharmacy distribution network and the connection of our innovative device to its Gluci-Chek solution present undeniable benefits for all healthcare professionals but also and above all for diabetic patients seeking a better quality of life, better comfort in the management and daily monitoring of their disease “, said Eric Dessertenne, CEO of BIOCORP.

“For more than 40 years, we’ve helped people with diabetes think less about their day-to-day management of their disease. We are committed to the autonomy and quality of life of patients with diabetes, by giving them the means to understand and act This is precisely what Mallya allows, integrated into our digital ecosystem for patients and healthcare professionals. health. added Frédéric Jacquey, President of Roche Diabetes Care France.

An innovation to improve the daily life and follow-up of diabetic patients on insulin

After the creation of insulin for therapeutic purposes 100 years ago, innovation continues in the field of diabetes, with the same ambition: to enable more and more patients to live better with their diabetes on a daily basis, a high stake for patients treated with insulin. To this end, Mallya collects and transfers insulin data in real time5 on their smartphone.

Once the device is installed, the patient selects and injects his insulin units as usual, the data transfer (date, time, selected dose) taking place automatically. While 37%6 of diabetic patients felt more anxious about their condition during their first Covid19 delivery, the simple and precise2 The Mallya device makes it easier for them to follow the progress of their disease. This could thus contribute to more serenity, more security and less errors or forgetfulness in taking their treatment.

Shared with healthcare professionals3 through the dedicated Roche Diabetes Care platform, precise and complete insulin data2 allows them to follow – face to face or from a distance – the evolution of their patients’ disease, refine their interpretation and help adjust treatment decisions.

A device integrated into a global solution to facilitate the management of diabetes

The device improves Roche Diabetes Care France’s digital ecosystem for integrated and personalized diabetes management. This solution was previously based on three elements: connected blood glucose meters (Accu-Chek® Mobile, Accu-Chek® Guide), the Gluci-Chek application and the Roche Diabetes Care platform dedicated to healthcare professionals. Mallya adds insulin data for more comprehensive patient monitoring.

Used regularly by more than 60,000 diabetic patients in France, this smartphone application combines three major functions for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a blood glucose self-monitoring diary and a graphic visualization. blood sugar results.

Once Mallya is connected to Gluci-Chek, the patient no longer has to manually declare their insulin doses, as the data is automatically displayed in the patient’s blood glucose log, for any compatible insulin pen.1. In a context where the French are once again confined and where 58%3 of diabetic patients did not have the feeling of having received special help during their first childbirth, this connected device allows real close monitoring.


Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has pioneered solutions to meet the needs of patients and healthcare professionals: medical devices (glucometers, self-pickers, insulin pumps), digital solutions (applications, platform for sharing blood glucose data between patients and health professionals) and services (assistance with information and therapeutic education). Through the implementation of a global solution linking medical devices and digital solutions, Roche Diabetes Care paves the way for personalized integrated diabetes management (iPDM), with the aim of facilitating and optimizing the management and the monitoring of this complex disease.

Roche Diabetes Care France is a subsidiary of the Roche group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, visit


Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical devices market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of the injected doses and thus offers better compliance in the treatment of diabetic patients. Available for sale from 2020, Mallya is the spearhead of BIOCORP’s product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP has been listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit

1 The Mallya medical device is compatible with Solostar (ref. 9828648001), FlexPen (ref. 9832360001) and KwikPen (ref. 9827587001) with the exception of Junior KwikPen pens from January 1, 2021. Market share calculation disposable insulin pens from the National Health Insurance Fund. Open the Medic 2019 database.

299% according to Mallya IFU version 6. Warning: some external factors may affect the accuracy of dose measurement or data transfer.

3If the patient decides to share their data.

4Source: IQVIA – LTD: Real-life analysis of BGM – Counter and strip markets – CMA February 2020 – Patients and volume.

5 As soon as Bluetooth is activated.

6 Online study conducted by CSA Research for Roche Diabetes Care France from May 18 to 27, 2020, with 504 diabetic patients (101 type1 diabetic patients and 403 type2 diabetic patients)

See the source version on

[]).push(function () { viAPItag.display(“vi_1088641796”) }) || []).push(function () { viAPItag.display(“vi_1088641796”) })


Please enter your comment!
Please enter your name here